Bojarska-Szmygin Anna, Janicki Krzysztof, Pietura Radosław, Janicka Lucyna
Laboratory of Nuclear Medicine, Cardinal Stefan Wyszynski Specialist Hospital, Lublin, Poland.
Ann Univ Mariae Curie Sklodowska Med. 2003;58(1):242-7.
The aim of the study was to assess the usefulness of determining the thyroid size, TRAb level and their correlation as markers for predicting the effectiveness of conservative treatment in Graves-Basedow's disease. The study included 100 patients with Graves-Basedow's disease; group I treated with thiamazole, group II treated with 131I. The biggest thyroid size, x -42.09+/-13.94ml, was found in the group unsuccessfully treated with thiamazole and was statistically significant compared to that in the euthyreosis group, x -31.65+/-11.74ml (p<0.01) and controls x -14.45+/-2.37ml (p<0.001). It is noteworthy that the initial TRAb level in the group with persistent hyperthyroidism was higher (x -54.39+/-31.21 U/I) than that in the euthyreosis group (x -29.13+/-19.44 U/I) and controls (x -2.75+/-2.06 U/l), p<0.001 for both parameters. Elevated antibody levels were also found after 12 and 18 months of treatment. Moreover, in the 131 I patients, the biggest thyroid size before iodine administration was found in the group with persistent hyperthyroidism, x -56.56+/-24.19 ml. It was statistically significantly different compared to the thyroid size in the euthyreosis patients x -37.922+/-20.69 ml (p<0.001) and in the hypothyreosis patients, x -43.47+/-18.09 ml (p<0.05). Before 131I administration, the highest antibody levels were observed in the group with persistent hyperthyroidism, x -103.61+/-43.90 U/I (p<0.001) compared to euthyreosis, hypothyreosis and control groups. The significance of differences in TRAb levels in the examined groups was still observed 18 months after 131I administration. In the groups of patients treated with thyreostatics and radioactive iodine, the positive correlation between the thyroid size and TRAb level was found before as well as 12 and 18 months after the onset of treatment.
1.The TRAb levels and thyroid sizes are important parameters that should be considered in predicting the effectiveness of treatment. 2. The TRAb level correlates with the thyroid size.
本研究的目的是评估测定甲状腺大小、促甲状腺素受体抗体（TRAb）水平及其相关性作为预测格雷夫斯-巴塞多氏病保守治疗效果标志物的有用性。该研究纳入了100例格雷夫斯-巴塞多氏病患者；第一组用甲巯咪唑治疗，第二组用131碘治疗。在用甲巯咪唑治疗未成功的组中发现最大甲状腺体积为x -42.09±13.94ml，与甲状腺功能正常组（x -31.65±11.74ml，p<0.01）和对照组（x -14.45±2.37ml，p<0.001）相比具有统计学意义。值得注意的是，持续性甲状腺功能亢进组的初始TRAb水平（x -54.39±31.21 U/I）高于甲状腺功能正常组（x -29.13±19.44 U/I）和对照组（x -2.75±2.06 U/l），这两个参数的p均<0.001。在治疗12个月和18个月后也发现抗体水平升高。此外，在接受131碘治疗的患者中，碘给药前甲状腺体积最大的是持续性甲状腺功能亢进组，x -56.56±24.19 ml。与甲状腺功能正常患者的甲状腺体积（x -37.922±20.69 ml，p<0.001）和甲状腺功能减退患者的甲状腺体积（x -43.47±18.09 ml，p<0.05）相比，具有统计学显著差异。在131碘给药前，持续性甲状腺功能亢进组观察到最高抗体水平，x -103.61±43.90 U/I（与甲状腺功能正常、甲状腺功能减退和对照组相比，p<0.001）。在131碘给药18个月后，仍观察到所检查组中TRAb水平差异的显著性。在用抗甲状腺药物和放射性碘治疗的患者组中，在治疗开始前以及治疗开始后12个月和18个月发现甲状腺大小与TRAb水平呈正相关。
1.TRAb水平和甲状腺大小是预测治疗效果时应考虑的重要参数。2.TRAb水平与甲状腺大小相关。
